CIK 0001534120 · Non-accelerated filer<br>Smaller reporting company
Avalo Therapeutics, Inc.
Sign in to watch- Ticker
- AVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450705648
- Phone
- 410-522-8707
- Business address
- 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA, 19087
- Former names
- Cerecor Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,865,893
- in 5 filings, $1.9M under 10b5-1 plans
Net −$1,865,893. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-28 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Restricted Stock Units | −24,200 | 24,200 | ||
| 2026-03-28 | Chan Mitchell Director | Option exercise | +3,166 | 6,333 | ||
| 2026-03-28 | Chan Mitchell Director | Option exercise · Restricted Stock Units | −3,166 | 3,167 | ||
| 2026-03-28 | NEIL GARRY ARTHUR Chief Executive Officer | Option exercise | +64,866 | 112,006 | ||
| 2026-03-28 | NEIL GARRY ARTHUR Chief Executive Officer | Shares withheld for taxes | −21,892 | $13.89 | $304K | 90,114 |
| 2026-03-28 | NEIL GARRY ARTHUR Chief Executive Officer | Option exercise · Restricted Stock Units | −64,866 | 64,867 | ||
| 2026-03-28 | KAPLAN GILLA Director | Option exercise | +3,166 | 6,333 | ||
| 2026-03-28 | KAPLAN GILLA Director | Option exercise · Restricted Stock Units | −3,166 | 3,167 | ||
| 2026-03-16 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +19,500 | $12.65 | $247K | 23,122 |
| 2026-03-16 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +5,992 | $8.04 | $48K | 29,114 |
| 2026-03-16 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −25,492 | $16.15 | $412K | 3,622 |
| 2026-03-16 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −19,500 | 214,500 | ||
| 2026-03-16 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,992 | 149,008 | ||
| 2026-02-26 | Boyd Taylor Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2026-02-26 | Riley Jennifer Chief Strategy Officer | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2026-02-26 | Doyle Mittie Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2026-02-26 | Sullivan Christopher Ryan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2026-02-26 | VARKI PAUL Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2026-02-26 | NEIL GARRY ARTHUR Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +286,000 | 286,000 | ||
| 2025-12-31 | Lind Kevin Robert Director | Grant or award · Stock Option (Right to Buy) | +848 | $14.74 | $12K | 848 |
Page 7 of 11 · 202 trades